Aquestive Therapeutics Q2 revenue beats on Suboxone strength
AQST•Outlook and quarterly results
- Aquestive expects 2026 revenue of $46 mln to $50 mln
- Company sees 2026 non-GAAP adjusted EBITDA loss of $35 mln to $30 mln
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | $13.82 mln | $11.42 mln (8 Analysts) |
| Q2 Loss Per Share | $0.18 | ||
| Q2 Net Loss | $22.86 mln | ||
| Q2 Adjusted EBITDA | Beat | -$5.20 mln | -$7.95 mln (2 Analysts) |
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell". The average consensus recommendation for the pharmaceuticals peer group is "buy". Wall Street's median 12-month price target for Aquestive Therapeutics Inc is $10.00, about 133.1% above its August 10 closing price of $4.29.
Q2 revenue beats on higher Suboxone-related sales
- U.S. pharmaceutical developer's Q2 revenue rose 38% yr/yr, beating analyst expectations
- Net loss widened due to one-time debt extinguishment loss
Revenue growth was mainly driven by higher manufacture and supply revenue, primarily from increased Suboxone revenues. Higher license and royalty revenue, mainly from Zevra, also contributed to overall revenue growth.
The company produced more doses in Q2 2026 compared with Q2 2025, supporting higher revenue.
